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Abstract Using a heterologous yeast expression assay, we show
that inhibitor of apoptosis proteins (IAPs) suppress caspase-3-
mediated cytotoxicity in the order of XIAPs c-IAP2s c-
IAP1s survivin. The same ordering of IAP activities was
demonstrated in mammalian cells expressing an auto-activating
caspase-3. The relative anti-apoptotic activities of each IAP
depended on the particular death stimulus. For IAP-expressing
cells treated with camptothecin, survival correlated with their
intrinsic anti-caspase-3 activity. However, c-IAP1-transfected
cells were disproportionately resistant to tumor necrosis factor-
K, suggesting that its anti-apoptotic activities extend beyond
caspase-3 or -7 inhibition. Yeast-based caspase assays provide
rapid, reliable information on specificity and activity of the IAPs
and aid in identifying critical targets in mammalian apoptotic
pathways. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The family of caspase cysteine proteases is involved in car-
rying out programmed cell death in metazoans in a process
referred to as apoptosis [1]. There are 14 identi¢ed mamma-
lian caspases, each synthesized as a zymogen which becomes
activated through proteolytic cleavage at sites with aspartic
acid in the P1 position by a subset of activated caspases [1].
When cells receive signals to die, speci¢c caspases become
activated in a hierarchical fashion that leads to the processing
and activation of several critical e¡ector caspases [2]. One of
these e¡ector caspases, caspase-3, promotes cell disassembly
through the cleavage of several structural proteins and repair
enzymes necessary for cellular homeostasis. The proteolytic
activity of caspase-3 is a critical determinant of whether a
cell commits to death, and as a result, multicellular organisms
have evolved strategies to tightly regulate caspase-3 activity
within the cell [1].
One mechanism used to control caspase activity is the ex-
pression of endogenous protease inhibitors. The foremost ex-
ample is a family of caspase inhibitors called inhibitor of ap-
optosis proteins (IAPs) [3,4]. The IAPs were originally
described by an activity that prevents apoptotic cell deaths
caused by multiple triggers in Drosophila, Caenorhabditis ele-
gans and mammalian cells [5,6]. Subsequently, several labs
demonstrated by in vitro assays that IAPs function as direct
inhibitors for speci¢c caspases [7^9]. Speci¢cally, three mam-
malian IAPs, c-IAP1, c-IAP2, and XIAP, are direct inhibitors
of recombinant caspases-3, -7, and -9 [7^9]. This is generally
accepted to be the principal mechanism for the anti-apoptotic
activity of the IAPs in various experimental settings [4].
In this report, we examined the activities of the four known
mammalian IAPs, XIAP, c-IAP1, c-IAP2, and survivin, in
cellular assays dependent on caspase-3 function. Using a novel
functional assay based on heterologous expression in yeast, we
tested the ability of individual IAPs to correct a growth defect
in Saccharomyces cerevisiae expressing active human caspase-
3. Since yeasts lack endogenous caspases, this assay provides a
selective measure of IAP activity against the exogenously in-
troduced caspase. These results were compared with the anti-
apoptotic activities of these IAPs in mammalian cells express-
ing an activated caspase-3 or treated with tumor necrosis fac-
tor-K (TNFK) or camptothecin, a topoisomerase I inhibitor.
The di¡erent results with these assays of cellular IAP func-
tion indicate the importance of inhibiting multiple caspases in
mammalian apoptotic pathways and suggest that the in vivo
activity pro¢le is distinct for each IAP.
2. Materials and methods
2.1. Yeast cell culture and transformations
The S. cerevisiae W303-1A (MATa ade2-1 his3-11 his3-15 leu2-112
trp1-1 ura3-1) strain was used for the yeast expression studies. Trans-
formations were performed using lithium acetate. One tenth volume
of each transformation reaction was plated onto selective media in-
cluding 0.5 mM ZnCl2. This concentration of ZnCl2 had no e¡ect on
normal yeast growth or caspase-3-mediated cytotoxicity in yeast (data
not shown). Yeast colony counts were determined 48 or 96 h after
plating at 30‡C. Colony counts were determined in triplicate.
2.2. Construction of the pRS424GAL1-10 yeast expression vector and
derivatives
The pRS424GAL1-10 yeast expression vector was constructed by
ligating a EcoRI^BamHI fragment containing the complete GAL1-10
promoter from the pBM150 plasmid into the 2W pRS424 episomal
vector [10]. The pRS424GAL1-10-caspase-3 vector was constructed
by inserting a EcoRI^XhoI cDNA fragment encoding the 17 kDa
subunit of caspase-3 (amino acids 1^175) downstream of the GAL1
promoter and inserting a BamHI^SacI cDNA fragment encoding the
10 kDa subunit of caspase-3 (amino acids 179^277) downstream of
the GAL10 promoter. The 20 kDa and 10 kDa subunit cDNA frag-
ments of caspase-3 were ampli¢ed by polymerase chain reaction
(PCR).
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2.3. Cloning of inhibitor of apoptosis genes into mammalian and yeast
expression vectors
XIAP, c-IAP1, c-IAP2, and survivin cDNAs were PCR-ampli¢ed
from poly(A) RNA extracted from the human Jurkat T-cell line.
PCR primers added a c-myc epitope (EQKLISEEDL) in frame fol-
lowing the C-terminal residue. The c-myc-tagged IAP PCR products
were cloned into pcDNA3 mammalian and pYES2 yeast expression
vectors.
2.4. Construction of Bcl-XL, baculovirus p35, caspase-3 (C163S),
and dnFADD(81^209) mammalian and yeast expression vectors
Human Bcl-XL and baculovirus p35 cDNAs were cloned into the
pYES2 vector as EcoRI^XbaI fragments [11]. The dncaspase-3 con-
struct with an active site mutation (C163S) was derived by overlap
extension PCR mutagenesis of pcDNA3-caspase-3, converting cys-
teine 163 of caspase-3 to a serine [12,13]. The dnFADD (amino acids
81^209) construct was created by PCR ampli¢cation of pcDNA3-
FADD [14] and cloned into the pcDNA3 vector.
2.5. Immunoblotting assays
293HEK cells (1U106) were seeded into 100 mm dishes and trans-
fected the next day with 5 Wg of pcDNA3-IAP plasmids using calcium
phosphate. At 24 h post-transfection, cells were washed in ice-cold
phosphate-bu¡ered saline and resuspended in 500 Wl lysis bu¡er
(20 WM Tris^HCl pH 8.0, 100 mM NaCl, 0.1% Triton X-100, 1 mM
EDTA) supplemented with a protease inhibitor cocktail tablet
(Roche). The lysates were microcentrifuged at 10 000 rpm for
30 min. The protein concentration was quantitated by Bradford assay
(Bio-Rad). 50 Wg of protein was fractionated on 12% SDS^polyacryl-
amide gels followed by Western blot analysis using a monoclonal
antibody against the c-myc epitope (BabCo).
Fig. 1. Expression of caspase-3 inhibits yeast growth. A: W303-1A cells were transformed with pRS424GAL1-10-caspase-3 or control vector
along with the pYES2 vector and plated onto galactose- or glucose-selective media. Colony growth is shown at 48 h. B: W303-1A cells were
co-transformed with pRS424GAL1-10-caspase-3 and test cDNAs. Colony growth is shown at 48 h. The results are representative of at least
three independent experiments.
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2.6. Cell death assays
2.6.1. Reversed (rev) caspase-3-mediated cell death. 293HEK cells
were seeded at a density of 9.0U104 cells per well in 12 well tissue
culture plates. On day 2, cells were re-fed and the following day the
cells were co-transfected with 50 ng Of the pRSC-rev-caspase-3 vector
and 1450 ng of pcDNA3 vector or test pcDNA3 plasmids using cal-
cium phosphate. Cells were ¢xed in 0.5% glutaraldehyde at 24 h post-
transfection. Cells were incubated in X-gal staining solution overnight
at 37‡C. Dead cells were identi¢ed by a rounded, condensed morphol-
ogy, while viable cells were £attened and extended. Apoptosis was
determined as the ratio of apoptotic blue cells over the total number
of blue cells per well. A minimum of 300 blue cells was scored in
triplicate assays.
2.6.2. TNFK-mediated cell death. 293HEK cells were seeded at a
density of 5.0U104 cells per well in a 12 well tissue culture plate. On
day 2, the cells were re-fed and the following day the cells were co-
transfected with 2 ng of pcDNA3-L-galactosidase plasmid and 1500 ng
of the pcDNA3 vector or test pcDNA3 plasmids. The medium was
replaced at 24 h with medium (2% fetal calf serum) containing 80 ng/
ml of recombinant TNFK (RpD Systems). Apoptotic cells were
counted after 24 h as described above.
2.6.3. Camptothecin-mediated cell death. 293HEK cells were
seeded at a density of 5.0U104 cells per well in a 12 well tissue culture
plate. The cells were re-fed the next day. On day 3, the cells were co-
transfected with 2 ng pcDNA3-L-galactosidase plasmid and 1500 ng
of pcDNA3 vector or test plasmids. The medium was replaced at 24 h
with fresh medium containing 2 WM camptothecin (Sigma). The cells
were scored for apoptosis at 24 h.
3. Results
We previously reported that expression of active human
caspase-3 in S. cerevisiae results in severe growth delay and
inhibition of colony formation [15]. For co-transformation
studies, we generated a single yeast expression vector contain-
ing both 20 kDa and 10 kDa subunits of caspase-3 down-
stream of the GAL1 and GAL10 promoters, respectively.
Transformation of yeast with the pRS424GAL1-10(TRP1)-
caspase-3 vector inhibited colony formation on galactose-con-
taining (GAL) media (Fig. 1A). Colony formation in the
pRS424GAL1-10-caspase-3 transformants could be rescued
by co-expression of a strong caspase inhibitor, baculovirus
p35 protein (Fig. 1B) [15].
We employed this caspase-3-dependent phenotype in yeast
to test individual IAPs. Yeast were co-transformed with the
Fig. 2. Inhibition of caspase-3-mediated cytotoxicity in yeast by
IAPs. Relative colony frequency was assessed at 96 h following co-
transformation of pRS424GAL1-10-caspase-3 and pYES2 vectors ex-
pressing baculovirus p35, XIAP, c-IAP1, c-IAP2, survivin, or Bcl-
XL cDNAs.
C
Fig. 3. Inhibition of caspase-3-induced apoptosis by IAPs.
A: 293HEK cells stained for, L-galactosidase expression at 24 h
post-transfection with control plasmid (left) or pRSC-rev-caspase-3
(right). B: Western blot analysis of IAP protein expression in
293HEK cells. C: The pRSC-rev-caspase-3 plasmid was co-trans-
fected into 293HEK cells with test cDNAs. Apoptosis was assessed
at 24 h.
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pRS424GAL1-10-caspase-3 vector and a galactose-inducible
pYES2 vector with either c-IAP1, c-IAP2, XIAP, survivin,
baculovirus p35 or Bcl-XL cDNAs. XIAP expression restored
normal colony growth of caspase-3 transformants on GAL
medium as e¡ectively as baculovirus p35 (Fig. 1B). However,
no colonies formed on GAL plates by 48 h for c-IAP1,
c-IAP2, survivin and Bcl-XL co-transformants.
c-IAP1 and c-IAP2 are direct inhibitors of caspase-3 in
vitro, although their activities are 2^3 logs lower than XIAP
[8]. To quantitate lower levels of anti-caspase-3 activity, we
delayed counting colonies in the caspase-3 transformants on
GAL medium until 96 h to allow slower-growing colonies to
be scored. At 96 h, a small number of colonies are detected in
caspase-3 transformants. We expressed the growth delay in
caspase-3 transformants as relative colony frequency (RCF),
the ratio of colonies formed on GAL medium divided by
colonies on glucose-containing medium at 96 h. Co-transfor-
mation of pRS424GAL1-10-caspase-3 and the control pYES2
plasmid produced a RCF value of 0.23, while baculovirus p35
and XIAP produced RCF values close to 1 (Fig. 2). c-IAP1,
c-IAP2, and survivin gave intermediate results, with RCF val-
ues of 0.59, 0.66, and 0.48 respectively, while Bcl-XL, which
acts upstream of caspase activation in apoptosis, resulted in
an RCF value of 0.39 (Fig. 2).
We next examined the anti-apoptotic activity of individual
IAPs in mammalian apoptosis induced by transient overex-
pression of caspase-3. We introduced activated caspase-3 in
293HEK cells by transient transfection, using a pRSC expres-
sion vector harboring rev-caspase-3 [16]. The rearranged pro-
tein produced by this cDNA is more e⁄ciently processed in
transfected cells than native procaspase-3. Transfected cells
expressed L-galactosidase and appeared blue with X-gal stain-
ing (Fig. 3A). Transfection of rev-caspase-3 induced cell
shrinkage and nuclear condensation typical of apoptosis
(Fig. 3A).
Individual IAPs tagged with a myc epitope were expressed
at comparable levels in transfected 293HEK cells (Fig. 3B).
We co-transfected single IAPs with rev-caspase-3 and counted
L-galactosidase-positive cells at 24 h. As shown in Fig. 3C, co-
expression of XIAP with rev-caspase-3 decreased the percent-
age of blue cells with condensed nuclei (50.1%), while c-IAP2,
c-IAP1, and survivin provided less protection (61.7%, 73.1%,
and 75.4% apoptotic cells, respectively). Baculovirus p35 and
a dominant-negative mutant caspase-3 (C163S) were strongly
protective in this assay and decreased apoptosis to 11.3% and
17.2% respectively.
We compared these results to the ability of each IAP to
block apoptosis following death receptor signaling or geno-
toxic damage. At 24 h after transient transfection of
pcDNA3-IAP plasmids, we treated 293HEK cells with
TNFK or camptothecin. TNFK induced apoptosis in 77.0%
of mock-transfected 293HEK cells by 24 h, while co-trans-
fection of either baculovirus p35, dncaspase-3 (C163S), or a
dominant-negative FADD(89^209) reduced levels of apopto-
sis to 34.7%, 20.8%, and 16.9%, respectively (Fig. 4A). XIAP
and Bcl-XL provided an intermediate level of protection
against TNFK, decreasing apoptosis to 48.4% and 48.7%.
c-IAP1, which had relatively low activity against caspase-3
in both yeast and 293HEK cell assays, was as e¡ective as
Bcl-XL and XIAP in reducing TNFK-induced death (44.3%)
(Fig. 4A). In contrast, c-IAP2, which ranked second to XIAP
in caspase-3 inhibition, provided minimal resistance in TNFK-
induced apoptosis, along with survivin (64.8% and 69.1% re-
spectively).
Treatment of 293HEK cells with the DNA topoisomerase I
inhibitor, camptothecin, resulted in moderate levels of apo-
ptosis at 24 h (68.9%), which was inhibited by prior trans-
fection of baculovirus p35, Bcl-XL or dncaspase-3 (31.3%,
33.1%, and 33.7% apoptosis, respectively). XIAP was again
found to be the strongest inhibitor of the four IAPs for camp-
tothecin-induced apoptosis (36.9%), while c-IAP2, c-IAP1,
and survivin had lesser activities (48.1%, 57.1%, and 65.5%
apoptosis, respectively) (Fig. 4B).
4. Discussion
4.1. Suppression of a caspase-3-dependent phenotype in
S. cerevisiae
Functional studies on individual components of apoptotic
pathways in higher eukaryotes are complicated by problems
of redundancy and speci¢city, related to the existence of fam-
ilies of apoptotic e¡ectors/regulators and extensive crosstalk
between signaling pathways. The absence of endogenous ho-
mologs provides an advantage for functional analysis of se-
lected mammalian genes in yeast expression models [17,18].
Fig. 4. TNFK- and camptothecin-induced apoptotic cell deaths are
di¡erentially regulated by IAP proteins. 293HEK cells were transi-
ently transfected with test cDNAs. A: Apoptosis was assessed 24 h
after addition of TNFK. B: Apoptosis was assessed 24 h after treat-
ment with 2 WM camptothecin.
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Heterologous expression of the mammalian cell death regula-
tors Bcl-2 and Bax in S. cerevisiae has been utilized success-
fully to identify and test functional suppressors of these genes
[19]. We exploited the lack of endogenous caspases in yeast to
analyze the IAP class of caspase inhibitors in an in vivo set-
ting with a single introduced caspase. We previously showed
that co-transformation and expression of separate plasmids
encoding the 20 kDa and 10 kDa subunits of active cas-
pase-3 caused growth inhibition of S. cerevisiae [15].
Among individual IAPs tested, XIAP completely sup-
pressed caspase-3-mediated growth suppression in yeast, while
c-IAP1, c-IAP2, and survivin had lower, but detectable activ-
ities. These results are consistent with the in vitro activities of
each IAP against recombinant active caspase-3, with the ex-
ception of survivin [7^9]. It was recently reported that bacte-
rially expressed recombinant survivin, which binds to acti-
vated caspases-3 and -7, is inactive against caspase-3 in
vitro, although it provided some protection from apoptosis
induced by overexpression of procaspase-3 [20]. The yeast
experiments indicate that survivin is a bona ¢de, although
weak, in vivo inhibitor of caspase-3 [20]. The Kis of recombi-
nant XIAP, c-IAP2, and c-IAP1 for caspase-3 are 0.7 nM, 35
nM, and 108 nM, respectively [7,8]. These IAPs ranked in the
order XIAPs c-IAP2vc-IAP1 as in vivo inhibitors of cas-
pase-3 in yeast. Based on the RCF values, we can predict
that the Ki of survivin for caspase-3 is greater than that of
c-IAP1 (108 nM). Currently, di⁄culties with production of
bioactive survivin protein in bacteria preclude these studies.
The yeast heterologous expression system provides an alter-
native method for studying the relative inhibitory activities of
IAPs against individual caspases.
4.2. IAP and caspase-3 interactions in mammalian cells
We next tested the ability of each IAP to inhibit cell death
induced by overexpression of active caspase-3 in mammalian
cells. Each of the IAPs bind to processed caspase-3, and XIAP
and survivin have been demonstrated to inhibit apoptosis
caused by overexpression of procaspase-3 [20]. All of the
IAPs identi¢ed to date are inhibitors of multiple caspases
and their ability to inhibit apoptosis may depend on the spe-
ci¢c cellular apoptotic pathways activated as well as the spec-
trum of anti-caspase activity for each IAP. Co-transfection of
the IAPs with rev-caspase-3 suppressed apoptosis in 293HEK
cells in the order XIAPs c-IAP2s c-IAP1s survivin. These
results are consistent with the yeast expression studies, and
con¢rm that caspase-3 is the critical target in these cell death
assays.
4.3. IAPs in TNFK- and camptothecin-induced apoptosis
Stimuli for mammalian apoptosis are transmitted through
speci¢c signal transduction pathways that converge on the
proteolytic activation of one or more caspases [21,22]. We
extended our studies of IAPs in mammalian cells to investi-
gate their ability to suppress apoptosis after TNFR-I receptor
engagement or exposure to camptothecin, a DNA topoiso-
merase I inhibitor. There were distinct di¡erences observed
in the anti-apoptotic activities of the IAPs for these cell death
triggers. The dominant-negative mutant of caspase-3 (C163S)
e⁄ciently blocked TNFK-induced cell death, con¢rming the
importance of caspase-3 in apoptotic signaling downstream of
TNFK. As expected, XIAP, a potent inhibitor of caspases-3,
-7 and -9, e⁄ciently blocked TNFK-induced cell death [7,8].
Somewhat surprisingly, c-IAP1 also strongly inhibited TNFK-
induced cell death, and c-IAP2 and survivin had minimal
activity. Published studies have shown that c-IAP1 and
c-IAP2 are direct inhibitors of caspases-3, -7, and -9, suggest-
ing that these caspases are the principal targets of c-IAP1 and
c-IAP2 anti-apoptotic activity [8,9]. For caspase-3 and cas-
pase-7, cIAP2 has greater or equivalent inhibitory activity as
c-IAP1 [8]. In light of these ¢ndings, our results suggest that
c-IAP1 has additional activities that are important in regulat-
ing TNFK-induced apoptosis. C-IAP1 and c-IAP2 were ini-
tially identi¢ed in association with the TNFR-II receptor
complex and bind to the receptor-associated cytoplasmic pro-
teins, TRAF1 and TRAF2 [23]. c-IAP1 is also recruited to the
TNFR-I signaling complex upon receptor engagement and
blocks TNFK-induced cell death if co-expressed with
TRAF1/TRAF2 [24]. Di¡erences between c-IAP1 and
c-IAP2 in their e¡ects on TNFK signal transduction in
293HEK cells may contribute to their relative anti-apoptotic
e¡ects in this model.
Camptothecin, a DNA topoisomerase I inhibitor, induces
DNA double-stranded breaks and, like other genotoxic
agents, results in apoptosis secondary to mitochondrial release
of apoptogenic factors [23]. The IAPs block chemotherapy-
induced apoptosis in di¡erent experimental protocols [4]. For
camptothecin, the IAPs ranked in potency as XIAPs
c-IAP2s c-IAP1s survivin. In this case, the anti-apoptotic
activity of the IAPs in the camptothecin model tracks with
their ability to inhibit caspase-3 [7,8]. Like TNFK-induced
death, the dominant-negative caspase-3 mutant e⁄ciently
blocked camptothecin-induced apoptosis. Previous reports in-
dicate that chemotherapeutic drugs result in activation of cas-
pase-3 through the assembly of the APAF-1/cytochrome c/
caspase-9 apoptosome complex [25^27]. As XIAP, c-IAP1
and c-IAP2 block cytochrome c-induced activation of cas-
pase-9 as well as caspase-3 activity, the relative potency of
IAPs in camptothecin-induced apoptosis can be explained
by their known activities as caspase inhibitors [7^9].
In summary, we describe the use of a yeast heterologous
expression assay to evaluate the relative activity of IAP family
members as inhibitors of a speci¢c human caspase, caspase-3.
This novel in vivo system can be used in parallel with in vitro
biochemical studies of recombinant caspase inhibitor proteins
and provides an alternative method of analysis in the event
that bioactivity cannot be preserved during bacterial expres-
sion and puri¢cation. By correlating pro¢les of caspase inhib-
itory activity with studies of IAPs in apoptosis, additional
insights into how IAPs function in apoptosis can be gained.
In addition to inhibition of caspase activity and/or processing,
roles for IAPs in death receptor signaling and centrosome
regulation during the cell cycle have been proposed
[4,28,29]. Elucidating the relationships between IAPs and their
cellular targets should increase our understanding of their
functions during homeostasis and disease.
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